501Y.V2 and 501Y.V3 variants of SARS-CoV-2 lose binding to bamlanivimab <i>in vitro</i>
Haolin Liu, Pengcheng Wei, Qianqian Zhang, Zhongzhou Chen, Katja Aviszus, Walter Downing, Shelley Peterson, Lyndon Reynoso, Gregory P. Downey, Stephen K. Frankel, John W. Kappler, Philippa Marrack, Gongyi Zhang
Abstract
. Detailed analysis shows that the ~10-fold gain of binding affinity between ACE2 and Y501-RBD, which also exits in the high contagious variant B.1.1.7/501Y.V1 from the United Kingdom, is compromised by additional introduction of the K417/N/T mutation. Mutation of E484K leads to the loss of bamlanivimab binding to RBD, although this mutation does not affect the binding between RBD and ACE2.
Topics & Concepts
MutationIn vitroReceptorSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Binding siteVirologyMolecular biologyCoronavirus disease 2019 (COVID-19)AntibodyBiologyPlasma protein bindingChemistryGeneticsCell biologyMedicineGeneInternal medicineInfectious disease (medical specialty)DiseaseSARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesViral Infections and Outbreaks Research